Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAKK 56/07 Dasatinib First-Line Treatment in Gastrointestinal Stromal Tumors
2007-002047-24Phase 2Active
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Apr 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in gastrointestinal stromal tumor (GIST), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Metabolic response at 4 weeks. Started Apr 2008; status: active.
02
Drugs
dasatinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2007-002047-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002047-24.